Merck snags rights to NanoBio's adjuvant vaccine tech

After collaborating with the University of Michigan-spinout NanoBio over the past three years, Merck ($MRK) has signed off on a new licensing pact for the biotech's nanoemulsion adjuvant technology. NanoBio has been doing some studies on the new technology's ability to spur a strong immune response when used intranasally. The pharma giant gets exclusive rights to use it for an RSV vaccine and non-exclusive rights for use in an intranasal as well as a universal flu vaccine. NanoBio scored an upfront and milestones in the deal, but didn't disclose the terms. Release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.